Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.47 |
| ▸ | KDM1A | O60341 | 2/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | EED | O75530 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 2/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL994856 | 1.00 | MAOB (0.47) | MAOBKDM1ACHRNB2CHRNA4CHRM2 | |
| SCHEMBL30733533 | 1.00 | MAOB (0.47) | MAOBKDM1ACHRNB2CHRNA4CHRM2 | |
| Hydrochloric Acid SCHEMBL994709 | 0.98 | MAOB (0.46) | MAOBKDM1ACHRNB2CHRNA4CHRM2 | |
| Oxalic Acid SCHEMBL28136322 | 0.83 | KMT2A (0.38) | MAOBKDM1AF10MEN1ALDH1A1 | |
| SCHEMBL28524004 | 0.82 | ALDH1A1 (0.43) | MEN1ALDH1A1KMT2A | |
| SCHEMBL3411535 | 0.82 | KMT2A (0.47) | MEN1ALDH1A1KMT2A | |
| SCHEMBL4480785 | 0.80 | EPHX2 (0.49) | MEN1ALDH1A1KMT2A | |
| SCHEMBL19872325 | 0.78 | KDM1A (0.32) | MAOBKDM1ACHRNB2CHRNA4CHRM2 | |
| SCHEMBL22710505 | 0.77 | ALDH1A1 (0.53) | MEN1ALDH1A1KMT2AHTR2C | |
| SCHEMBL994345 | 0.76 | SLC6A2 (0.52) | MAOBKDM1ASLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119707784-A | Process for preparing amino acid derivatives | 株式会社API | 2025-03-28 | — | — | CN | disclosed |
| CN-112930338-B | Process for preparing amino acid derivatives | 株式会社API | 2024-12-24 | — | — | CN | disclosed |
| US-12103928-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2024-10-01 | — | — | US | disclosed |
| CN-117447285-A | Preparation method of chiral impurity of beta-lactamase inhibitor intermediate | 赤峰迪生药业有限责任公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-117447285-A | Preparation method of chiral impurity of beta-lactamase inhibitor intermediate | 赤峰迪生药业有限责任公司 | 2024-01-26 | — | — | CN | disclosed |
| US-20230331724-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2023-10-19 | — | — | US | disclosed |
| CN-116772561-A | But reuse's dehydrating agent drying equipment for medicine preparation | 常州红太阳药业有限公司 | 2023-09-19 | — | — | CN | disclosed |
| US-11731971-B2 | Processes for preparing a diazabicyclooctane compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2023-08-22 | — | — | US | disclosed |
| CN-115707686-A | Method for refining avibactam sodium initial raw material | 四川科伦药物研究院有限公司 | 2023-02-21 | — | — | CN | disclosed |
| US-11142499-B1 | Method of preparing 5R-[(benzyloxy) amino] piperidine-2S-carboxylic acid or a derivative thereof | XINFA PHARMACEUTICAL CO., LTD (CN) | 2021-10-12 | — | — | US | disclosed |
| WO-2019075990-A1 | SIMPLE PREPARATION METHOD FOR AVIBACTAM INTERMEDIATE | 新发药业有限公司 | 2019-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731971-B2 | Processes for preparing a diazabicyclooctane compound | FN1, BMP1, AZI2 | MAOB 258/4885KDM1A 790/4885CHRNB2 1025/4885 |
| US-11142499-B1 | Method of preparing 5R-[(benzyloxy) amino] piperidine-2S-carboxylic acid or a derivative thereof | GLUL, GRIN2D, GRIN2C | MAOB 2278/4885KDM1A 2158/4885CHRNB2 1672/4885 |
| US-20230331724-A1 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND | FN1, BMP1, AZI2 | MAOB 258/4885KDM1A 790/4885CHRNB2 1025/4885 |
| US-12103928-B2 | Processes for preparing a diazabicyclooctane compound | FN1, BMP1, AZI2 | MAOB 258/4885KDM1A 790/4885CHRNB2 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.